Comparison between suba Itraconazole (SB) and conventional Itraconazole in the treatment of dermatophytosis.
Phase 4
Completed
- Conditions
- Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified
- Registration Number
- CTRI/2021/11/038062
- Lead Sponsor
- Dr Bikash Ranjan Kar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
All patients of dermatophytosis beyond 18 year of age.
Exclusion Criteria
1. Patients with prior use of systemic and/or topical antifungals in last 1 month.
2. Pregnancy and lactation
3. Deranged hepatic and renal status.
4. Diabetes mellitus.
5. History of cardiac disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare the efficacy of itraconazole 100 mg twice daily dosing with SB itraconazole 50 mg twice daily at the end of two weeks in dermatophytosis.Timepoint: At end of 2 weeks.
- Secondary Outcome Measures
Name Time Method Compare the safety of itraconazole 100 mg twice daily dosing with SB itraconazole 50 mg twice daily at the end of two weeks in dermatophytosis.Timepoint: At the end of 2 weeks.